TARGET VALIDATION METHODS FOR NEMATODE CONTROL AGENTS

Information

  • Research Project
  • 6485841
  • ApplicationId
    6485841
  • Core Project Number
    R44AI050313
  • Full Project Number
    2R44AI050313-02
  • Serial Number
    50313
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2001 - 22 years ago
  • Project End Date
    8/31/2004 - 19 years ago
  • Program Officer Name
    GOTTLIEB, MICHAEL
  • Budget Start Date
    9/1/2002 - 21 years ago
  • Budget End Date
    8/31/2003 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/30/2002 - 21 years ago
Organizations

TARGET VALIDATION METHODS FOR NEMATODE CONTROL AGENTS

DESCRIPTION (Provided by applicant): Infections by roundworm parasites, called nematodes, result in human mortality and morbidity, especially in subtropical and tropical regions of Africa, Asia, and the Americas. The World Health Organization estimates 2.9 billion people are infected. There are 595 known nematode parasites of vertebrates including hundreds that infect domesticated animals. Widespread use of drugs to control parasites over several decades has led to the evolution of drug-resistant forms of several nematode parasites. The rewards for the development of a new anthelmintic class are substantial. In phase II of our research, we aim to identify -100 genes that are essential to the model nematode Caenorhabditis elegans. We will then clone homologs of these genes from a range of free-living and parasitic nematodes. Using RNAi technology on the free-living nematodes, we will determine which homologs are essential to the nematode lifecycle. Genes that prove essential to all the nematodes tested will be designated as potential nematicide targets. In collaboration with academic laboratories, we will use RNAi to validate target genes in parasitic nematodes. We will test potential inhibitors of the most promising target genes because such compounds could lead to new anti-nematode therapies.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    318390
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:318390\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DIVERGENCE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAINT LOUIS
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    63132
  • Organization District
    UNITED STATES